Compositions and Methods of Treatment of Inflammatory Skin Conditions Using Allantoin

Abstract

Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof. Symptoms treated may include pain, inflammation, redness, itching, scarring, skin thickening, milia, or a combination thereof.

1 - 49 . (canceled) 
     
     
         50 . A method of treating an inflammatory skin condition in a patient comprising administering a composition comprising allantoin in an amount from about 2.5% to about 15% by weight and a pharmaceutically acceptable excipient, wherein said inflammatory skin condition in said patient is treated. 
     
     
         51 . The method of  claim 50 , wherein the composition is administered to the patient daily. 
     
     
         52 . The method of  claim 50 , wherein the allantoin is in an amount of about 3.0% to about 9.0%. 
     
     
         53 . The method of  claim 50 , wherein the composition results in penetration of the allantoin across the skin membrane of the patient in a dose dependent manner. 
     
     
         54 . The method of  claim 50 , wherein the composition results in penetration of the allantoin across the skin membrane of the patient without an increase in systemic blood levels of allantoin in the patient. 
     
     
         55 . The method of  claim 50 , wherein the composition is an oil-in-water emulsion further comprising an emollient and an emulsifier. 
     
     
         56 . The method of  claim 55 , wherein the emollient is selected from the group consisting of lanolin oil, cod liver oil, mineral oil, an alcohol, and any combination thereof. 
     
     
         57 . The method of  claim 55 , wherein the emulsifier is selected from the group consisting of sodium laurate sulfate, a white wax, and a combination thereof. 
     
     
         58 . The method of  claim 55 , wherein the composition further comprises a pH modifier, a solubilizing agent, an antioxidant, a preservative, a chelating agent, a viscosity agent or any combination thereof. 
     
     
         59 . The method of  claim 58 , wherein the pH modifier is citric acid; the solubilizing agent is propylene glycol; the antioxidant is butylated hydroxytoluene (BHT); the preservative is selected from the group consisting of methylparaben, propylparaben, and a combination thereof; the chelating agent is tetrasodium EDTA; the viscosity agent is selected from the group consisting of cetyl alcohol, stearyl alcohol, and a combination thereof; and the pharmaceutically acceptable excipient is water. 
     
     
         60 . The method of  claim 50 , wherein the composition further comprises an emollient, an emulsifier, a solvent, a pH modifier, a solubilizing agent, an antioxidant, a preservative, a chelating agent, an additive, a viscosity agent or a combination thereof. 
     
     
         61 . The method of  claim 50 , wherein the pH of the composition is about 4.0 to about 5.5 at room temperature. 
     
     
         62 . The method of  claim 50 , wherein the inflammatory skin condition is selected from the group consisting of cutaneous porphyria, sclerodema, decubitus ulcers, pressure ulcers, venous stasis ulcers, sickle cell ulcers, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, rosacea, miliaria, inflammation due to skin infections, post-operative care of incisions, post-operative inflammation, inflammation due to dry, cracked or aged skin, skin lines, a combination thereof and a symptom thereof. 
     
     
         63 . The method of  claim 62 , wherein the symptom is selected from a group consisting of inflammation, scarring, milia, skin thickening, redness, and a combination thereof. 
     
     
         64 . A composition comprising an oil-in-water emulsion comprising allantoin in an amount from about 2.5% to about 15% by weight and a pharmaceutically acceptable excipient. 
     
     
         65 . The composition of  claim 64  which when administered to a patient results in penetration of the allantoin across the skin membrane of the patient in a dose dependent manner. 
     
     
         66 . The composition of  claim 64  which when administered to a patient results in penetration of the allantoin across the skin membrane of the patient without an increase in systemic blood levels of allantoin in the patient.